Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

China Pharma and Biotech Market Update - Nov 23, 2010

|Includes: Novo Nordisk A/S (NVO)
Possible pricing panic? An early and unofficial report from an industry insider posted on a local website last week suggests that the upcoming second version of the "Measures for the Administration of Drug Price (Draft)" will gradually eliminate separate pricing for originator drugs. Specifically, the inside report indicates that the NDRC will set a transition period of four-years, during which government will gradually reduce differences between separate and general drug maximum pricing. For more on this issue, which puts many MNC pharmas and their branded generics under pressure, see Volume 41 of the China Pharmaceutical & Biotechnology Review . (GBI SOURCE users will find the article in the Special Reports section .)
Mercky future for Zocor? The SFDA has issued an ADR warning for simvastatin, warning of an increased risk of rhabdomyolysis when co-administered with amiodarone (an antiarrhythmic agent). Click on this week's SOURCE Snapshot for details of other HMG-CoA reductase inhibitors (or Statins) and combinations available in China.
source sanpshot
 
Novo stays focused on its sweet spot: Novo Nordisk revealed last week that its recently-announced Beijing (diabetes) R&D center expansion has a budget of USD 100 million - with up to USD 40 million earmarked for new labs that should be operational by the end of 2011. Novo also released results of a 3-month survey undertaken with the Chinese Medical Association involving over 5,900 subjects with Type II diabetes, which revealed a high number of patients with poorly controlled blood glucose levels and a high prevalence of diabetic complications. In other MNC news, Xian-Janssen and Tsinghua University launched a five-year collaboration designed to accelerate R&D in the area of infectious diseases.
Clinical Path-ology: the MOH further announced plans to release a list of over 100 disease categories that will be covered by the clinical pathway management system and to promote the system in all level three hospitals nationwide. The clinical pathway system may be an important determinant of formulary choices and practice and prescribing patterns going forward. For details, the article in Volume 34 of the China Pharmaceutical & Biotechnology Review . (GBI SOURCE users will find the article in the Special Reports section .)
Also last week, Hutchison MediPharma completed a private placement of USD 12.5 million from Mitsui & Company Ltd. (Mitsui received convertible preferred shares for a 12.2% stake of the enlarged share capital of Hutchison); the Russian Ministry of Health commissioned Anhui Huayuan Pharma as its agent in China responsible for registration and other pharmaceutical transactions involving Chinese drug companies entering the Russian market; Lansen Pharmaceutical acquired a 20% stake of Zhejiang Starry Pharmaceutical for RMB 160 million in a move expected to expand Lansen's presence in API sector, (a sector that, at the recent API China 2010 meeting, many agreed was seeing reduced growth rates); and the Hong Kong Department of Health reported a confirmed case of Influenza A virus subtype H5N1 - has bird flu come back to roost? Don't let a lack of China healthcare data ruffle your feathers, take a gander at our website: www.gbipharma.com - you'll crow with delight at our useful information.
Possible pricing panic? An early and unofficial report from an industry insider posted on a local website last week suggests that the upcoming second version of the "Measures for the Administration of Drug Price (Draft)" will gradually eliminate separate pricing for originator drugs. Specifically, the inside report indicates that the NDRC will set a transition period of four-years, during which government will gradually reduce differences between separate and general drug maximum pricing. For more on this issue, which puts many MNC pharmas and their branded generics under pressure, see Volume 41 of the China Pharmaceutical & Biotechnology Review . (GBI SOURCE users will find the article in the Special Reports section .)
Mercky future for Zocor? The SFDA has issued an ADR warning for simvastatin, warning of an increased risk of rhabdomyolysis when co-administered with amiodarone (an antiarrhythmic agent). Click on this week's SOURCE Snapshot for details of other HMG-CoA reductase inhibitors (or Statins) and combinations available in China.
source sanpshot
 
Novo stays focused on its sweet spot: Novo Nordisk revealed last week that its recently-announced Beijing (diabetes) R&D center expansion has a budget of USD 100 million - with up to USD 40 million earmarked for new labs that should be operational by the end of 2011. Novo also released results of a 3-month survey undertaken with the Chinese Medical Association involving over 5,900 subjects with Type II diabetes, which revealed a high number of patients with poorly controlled blood glucose levels and a high prevalence of diabetic complications. In other MNC news, Xian-Janssen and Tsinghua University launched a five-year collaboration designed to accelerate R&D in the area of infectious diseases.
Clinical Path-ology: the MOH further announced plans to release a list of over 100 disease categories that will be covered by the clinical pathway management system and to promote the system in all level three hospitals nationwide. The clinical pathway system may be an important determinant of formulary choices and practice and prescribing patterns going forward. For details, the article in Volume 34 of the China Pharmaceutical & Biotechnology Review . (GBI SOURCE users will find the article in the Special Reports section .)
Also last week, Hutchison MediPharma completed a private placement of USD 12.5 million from Mitsui & Company Ltd. (Mitsui received convertible preferred shares for a 12.2% stake of the enlarged share capital of Hutchison); the Russian Ministry of Health commissioned Anhui Huayuan Pharma as its agent in China responsible for registration and other pharmaceutical transactions involving Chinese drug companies entering the Russian market; Lansen Pharmaceutical acquired a 20% stake of Zhejiang Starry Pharmaceutical for RMB 160 million in a move expected to expand Lansen's presence in API sector, (a sector that, at the recent API China 2010 meeting, many agreed was seeing reduced growth rates); and the Hong Kong Department of Health reported a confirmed case of Influenza A virus subtype H5N1 - has bird flu come back to roost? Don't let a lack of China healthcare data ruffle your feathers, take a gander at our website: www.gbipharma.com - you'll crow with delight at our useful information.
Possible pricing panic? An early and unofficial report from an industry insider posted on a local website last week suggests that the upcoming second version of the "Measures for the Administration of Drug Price (Draft)" will gradually eliminate separate pricing for originator drugs. Specifically, the inside report indicates that the NDRC will set a transition period of four-years, during which government will gradually reduce differences between separate and general drug maximum pricing. For more on this issue, which puts many MNC pharmas and their branded generics under pressure, see Volume 41 of the China Pharmaceutical & Biotechnology Review . (GBI SOURCE users will find the article in the Special Reports section .)
Mercky future for Zocor? The SFDA has issued an ADR warning for simvastatin, warning of an increased risk of rhabdomyolysis when co-administered with amiodarone (an antiarrhythmic agent). Click on this week's SOURCE Snapshot for details of other HMG-CoA reductase inhibitors (or Statins) and combinations available in China.
source sanpshot
 
Novo stays focused on its sweet spot: Novo Nordisk revealed last week that its recently-announced Beijing (diabetes) R&D center expansion has a budget of USD 100 million - with up to USD 40 million earmarked for new labs that should be operational by the end of 2011. Novo also released results of a 3-month survey undertaken with the Chinese Medical Association involving over 5,900 subjects with Type II diabetes, which revealed a high number of patients with poorly controlled blood glucose levels and a high prevalence of diabetic complications. In other MNC news, Xian-Janssen and Tsinghua University launched a five-year collaboration designed to accelerate R&D in the area of infectious diseases.
Clinical Path-ology: the MOH further announced plans to release a list of over 100 disease categories that will be covered by the clinical pathway management system and to promote the system in all level three hospitals nationwide. The clinical pathway system may be an important determinant of formulary choices and practice and prescribing patterns going forward. For details, the article in Volume 34 of the China Pharmaceutical & Biotechnology Review . (GBI SOURCE users will find the article in the Special Reports section .)
Also last week, Hutchison MediPharma completed a private placement of USD 12.5 million from Mitsui & Company Ltd. (Mitsui received convertible preferred shares for a 12.2% stake of the enlarged share capital of Hutchison); the Russian Ministry of Health commissioned Anhui Huayuan Pharma as its agent in China responsible for registration and other pharmaceutical transactions involving Chinese drug companies entering the Russian market; Lansen Pharmaceutical acquired a 20% stake of Zhejiang Starry Pharmaceutical for RMB 160 million in a move expected to expand Lansen's presence in API sector, (a sector that, at the recent API China 2010 meeting, many agreed was seeing reduced growth rates); and the Hong Kong Department of Health reported a confirmed case of Influenza A virus subtype H5N1 - has bird flu come back to roost? Don't let a lack of China healthcare data ruffle your feathers, take a gander at our website: www.gbipharma.com - you'll crow with delight at our useful information.
Possible pricing panic? An early and unofficial report from an industry insider posted on a local website last week suggests that the upcoming second version of the "Measures for the Administration of Drug Price (Draft)" will gradually eliminate separate pricing for originator drugs. Specifically, the inside report indicates that the NDRC will set a transition period of four-years, during which government will gradually reduce differences between separate and general drug maximum pricing. For more on this issue, which puts many MNC pharmas and their branded generics under pressure, see Volume 41 of the China Pharmaceutical & Biotechnology Review . (GBI SOURCE users will find the article in the Special Reports section .)
Mercky future for Zocor? The SFDA has issued an ADR warning for simvastatin, warning of an increased risk of rhabdomyolysis when co-administered with amiodarone (an antiarrhythmic agent). Click on this week's SOURCE Snapshot for details of other HMG-CoA reductase inhibitors (or Statins) and combinations available in China.
source sanpshot
 
Novo stays focused on its sweet spot: Novo Nordisk revealed last week that its recently-announced Beijing (diabetes) R&D center expansion has a budget of USD 100 million - with up to USD 40 million earmarked for new labs that should be operational by the end of 2011. Novo also released results of a 3-month survey undertaken with the Chinese Medical Association involving over 5,900 subjects with Type II diabetes, which revealed a high number of patients with poorly controlled blood glucose levels and a high prevalence of diabetic complications. In other MNC news, Xian-Janssen and Tsinghua University launched a five-year collaboration designed to accelerate R&D in the area of infectious diseases.
Clinical Path-ology: the MOH further announced plans to release a list of over 100 disease categories that will be covered by the clinical pathway management system and to promote the system in all level three hospitals nationwide. The clinical pathway system may be an important determinant of formulary choices and practice and prescribing patterns going forward. For details, the article in Volume 34 of the China Pharmaceutical & Biotechnology Review . (GBI SOURCE users will find the article in the Special Reports section .)
Also last week, Hutchison MediPharma completed a private placement of USD 12.5 million from Mitsui & Company Ltd. (Mitsui received convertible preferred shares for a 12.2% stake of the enlarged share capital of Hutchison); the Russian Ministry of Health commissioned Anhui Huayuan Pharma as its agent in China responsible for registration and other pharmaceutical transactions involving Chinese drug companies entering the Russian market; Lansen Pharmaceutical acquired a 20% stake of Zhejiang Starry Pharmaceutical for RMB 160 million in a move expected to expand Lansen's presence in API sector, (a sector that, at the recent API China 2010 meeting, many agreed was seeing reduced growth rates); and the Hong Kong Department of Health reported a confirmed case of Influenza A virus subtype H5N1 - has bird flu come back to roost? Don't let a lack of China healthcare data ruffle your feathers, take a gander at our website: www.gbipharma.com - you'll crow with delight at our useful information.
Possible pricing panic? An early and unofficial report from an industry insider posted on a local website last week suggests that the upcoming second version of the "Measures for the Administration of Drug Price (Draft)" will gradually eliminate separate pricing for originator drugs. Specifically, the inside report indicates that the NDRC will set a transition period of four-years, during which government will gradually reduce differences between separate and general drug maximum pricing. For more on this issue, which puts many MNC pharmas and their branded generics under pressure, see Volume 41 of the China Pharmaceutical & Biotechnology Review . (GBI SOURCE users will find the article in the Special Reports section .)
Mercky future for Zocor? The SFDA has issued an ADR warning for simvastatin, warning of an increased risk of rhabdomyolysis when co-administered with amiodarone (an antiarrhythmic agent). Click on this week's SOURCE Snapshot for details of other HMG-CoA reductase inhibitors (or Statins) and combinations available in China.
source sanpshot
 
Novo stays focused on its sweet spot: Novo Nordisk revealed last week that its recently-announced Beijing (diabetes) R&D center expansion has a budget of USD 100 million - with up to USD 40 million earmarked for new labs that should be operational by the end of 2011. Novo also released results of a 3-month survey undertaken with the Chinese Medical Association involving over 5,900 subjects with Type II diabetes, which revealed a high number of patients with poorly controlled blood glucose levels and a high prevalence of diabetic complications. In other MNC news, Xian-Janssen and Tsinghua University launched a five-year collaboration designed to accelerate R&D in the area of infectious diseases.
Clinical Path-ology: the MOH further announced plans to release a list of over 100 disease categories that will be covered by the clinical pathway management system and to promote the system in all level three hospitals nationwide. The clinical pathway system may be an important determinant of formulary choices and practice and prescribing patterns going forward. For details, the article in Volume 34 of the China Pharmaceutical & Biotechnology Review . (GBI SOURCE users will find the article in the Special Reports section .)
Also last week, Hutchison MediPharma completed a private placement of USD 12.5 million from Mitsui & Company Ltd. (Mitsui received convertible preferred shares for a 12.2% stake of the enlarged share capital of Hutchison); the Russian Ministry of Health commissioned Anhui Huayuan Pharma as its agent in China responsible for registration and other pharmaceutical transactions involving Chinese drug companies entering the Russian market; Lansen Pharmaceutical acquired a 20% stake of Zhejiang Starry Pharmaceutical for RMB 160 million in a move expected to expand Lansen's presence in API sector, (a sector that, at the recent API China 2010 meeting, many agreed was seeing reduced growth rates); and the Hong Kong Department of Health reported a confirmed case of Influenza A virus subtype H5N1 - has bird flu come back to roost? Don't let a lack of China healthcare data ruffle your feathers, take a gander at our website: www.gbipharma.com - you'll crow with delight at our useful information.
Possible pricing panic? An early and unofficial report from an industry insider posted on a local website last week suggests that the upcoming second version of the "Measures for the Administration of Drug Price (Draft)" will gradually eliminate separate pricing for originator drugs. Specifically, the inside report indicates that the NDRC will set a transition period of four-years, during which government will gradually reduce differences between separate and general drug maximum pricing. For more on this issue, which puts many MNC pharmas and their branded generics under pressure, see Volume 41 of the China Pharmaceutical & Biotechnology Review . (GBI SOURCE users will find the article in the Special Reports section .)

Mercky future for Zocor? The SFDA has issued an ADR warning for simvastatin, warning of an increased risk of rhabdomyolysis when co-administered with amiodarone (an antiarrhythmic agent). Click on this week's SOURCE Snapshot for details of other HMG-CoA reductase inhibitors (or Statins) and combinations available in China.

Novo stays focused on its sweet spot: Novo Nordisk revealed last week that its recently-announced Beijing (diabetes) R&D center expansion has a budget of USD 100 million - with up to USD 40 million earmarked for new labs that should be operational by the end of 2011. Novo also released results of a 3-month survey undertaken with the Chinese Medical Association involving over 5,900 subjects with Type II diabetes, which revealed a high number of patients with poorly controlled blood glucose levels and a high prevalence of diabetic complications. In other MNC news, Xian-Janssen and Tsinghua University launched a five-year collaboration designed to accelerate R&D in the area of infectious diseases.

Clinical Path-ology: the MOH further announced plans to release a list of over 100 disease categories that will be covered by the clinical pathway management system and to promote the system in all level three hospitals nationwide. The clinical pathway system may be an important determinant of formulary choices and practice and prescribing patterns going forward. For details, the article in Volume 34 of the China Pharmaceutical & Biotechnology Review . (GBI SOURCE users will find the article in the Special Reports section .)

Also last week, Hutchison MediPharma completed a private placement of USD 12.5 million from Mitsui & Company Ltd. (Mitsui received convertible preferred shares for a 12.2% stake of the enlarged share capital of Hutchison); the Russian Ministry of Health commissioned Anhui Huayuan Pharma as its agent in China responsible for registration and other pharmaceutical transactions involving Chinese drug companies entering the Russian market; Lansen Pharmaceutical acquired a 20% stake of Zhejiang Starry Pharmaceutical for RMB 160 million in a move expected to expand Lansen's presence in API sector, (a sector that, at the recent API China 2010 meeting, many agreed was seeing reduced growth rates); and the Hong Kong Department of Health reported a confirmed case of Influenza A virus subtype H5N1 - has bird flu come back to roost? Don't let a lack of China healthcare data ruffle your feathers, take a gander at our website: www.gbipharma.com - you'll crow with delight at our useful information

Disclosure: no position